Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH -2.05%53 EV-to-EBITDA is -4.76 as of Jul. 22, 2026. GuruFocus rates ASX:AVH with a GF Score™ of 53/100 and a GF Value™ of A$3.12 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 510 Medical Devices & Instruments companies, AVITA Medical ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AVITA Medical's enterprise value is A$268.4 Mil.
AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-56.4 Mil. Therefore, AVITA Medical's EV-to-EBITDA for today is -4.76.
The historical rank and industry rank for AVITA Medical's EV-to-EBITDA or its related term are showing as below:
ASX:AVH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -260.22 Med: -6.54 Max: -1.04
Current: -4.96
During the past 13 years, the highest EV-to-EBITDA of AVITA Medical was -1.04. The lowest was -260.22. And the median was -6.54.
ASX:AVH's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.93
vs ASX:AVH: -4.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
AVITA Medical (ASX:AVH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AVITA Medical's PE Ratio (TTM) for today is calculated as:
AVITA Medical's share price for today is A$1.43.
AVITA Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-0.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AVITA Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVH vs MXCT, HYPR, ZOMDF: EV-to-EBITDA Comparison
For the Medical Devices subindustry, AVITA Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AVITA Medical's EV-to-EBITDA falls into.
AVITA Medical's current Enterprise Value is A$268.4 Mil.
AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-56.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (ASX:AVH) has a EV-to-EBITDA of -4.76 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AVITA Medical. According to the industry distribution chart, AVITA Medical ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is AVITA Medical's EV-to-EBITDA too high?
AVITA Medical's current EV-to-EBITDA is -4.76. Based on the distribution chart, AVITA Medical ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's EV-to-EBITDA compare to MXCT and HYPR?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #999999 out of 510 companies for EV-to-EBITDA. This places AVITA Medical in the lower half of its industry. The industry median EV-to-EBITDA is 13.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AVITA Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current EV-to-EBITDA is -4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.12, compared to a current price of A$1.43 — trading 54.2% below its estimated fair value. The current EV-to-EBITDA is -4.76. AVITA Medical's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current EV-to-EBITDA is -4.76 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$1.43 is trading 54.2% below its estimated GF Value™ of A$3.12.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
EV-to-EBITDA: -4.76
GF Value™: A$3.12 vs. price of A$1.43 (54.2% below fair value)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
53GF Score
Get the complete analysis for ASX:AVH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
